StockNews.AI
PEPG
StockNews.AI
61 days

The Gross Law Firm Notifies PepGen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PEPG

1. Class action notice issued for PepGen shareholders regarding misleading statements. 2. Allegations involve issues with PGN-EDO51's effectiveness and safety. 3. Potential halting of CONNECT2 study raises doubts about PEPG's future prospects. 4. Shareholders encouraged to register by August 8, 2025, for recovery. 5. Gross Law Firm aims to protect investors' rights against deceitful practices.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations, if substantiated, could lead to significant drops in PEPG's stock price, akin to past cases like Immunomedics, which saw price declines upon negative regulatory news.

How important is it?

The ongoing legal issues, especially regarding regulatory compliance and product efficacy, significantly impact PEPG's market credibility and investor trust.

Why Long Term?

Trial outcomes and potential impacts on PEPG's product pipeline will take time to unfold, affecting investor perception and stock performance over the long term.

Related Companies

NEW YORK, June 19, 2025 /PRNewswire/ --

The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).

Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=153525&from=4

CLASS PERIOD:

March 7, 2024 to March 3, 2025

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that:

  1. the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe;
  2. phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval;
  3. as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated;
  4. as a result, defendants' public statements were materially false and misleading at all relevant times.

DEADLINE:

August 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=153525&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of PEPG during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 8, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

SOURCE The Gross Law Firm

Related News